Literature DB >> 23568138

Clinical features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in northeast Iran.

Ali Shoeibi1, Houshang Rafatpanah, Amir Azarpazhooh, Naghme Mokhber, Mohammad Reza Hedayati-Moghaddam, Amin Amiri, Peyman Hashemi, Mohsen Foroghipour, Reza Farid Hoseini, Ali Bazarbachi, Mahmoud Reza Azarpazhooh.   

Abstract

This study aimed to introduce clinical manifestations of patients in northeast Iran with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and describe the epidemiological features, as well as risk factors for HTLV-1 infection. This is a cross-sectional study of HTLV-1 infected cases and HAM/TSP patients referred by outpatient neurology clinics as well as Mashhad Blood Transfusion Center from 2005 to 2010. The study comprises 513 cases, including 358 healthy carriers (HCs) and 145 HAM/TSP patients. The majority of carriers were male (73.5%), whereas 67.6% of HAM/TSP sufferers were female (P < 0.001). The mean age of HAM/TSP patients and HCs was 45.9 ± 13.6 and 39.5 ± 11.58 years, respectively (P < 0.001). The history of transfusion, surgery, hospitalization and cupping was observed in a significant greater number of HAM/TSP patients than the HCs (P < 0.001, P < 0.001, P < 0.001 and P = 0.029, respectively). Gait disturbance was the most common complaint in HAM/TSP patients (72.4%). This research develops an HTLV-1 data registry in an endemic area such as Mashhad which can serve useful purposes, including evaluation of clinical and laboratory characteristics of HAM/TSP patients and epidemiological data of HTLV-1-infected cases.

Entities:  

Mesh:

Year:  2013        PMID: 23568138     DOI: 10.1007/s13760-013-0194-6

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  6 in total

1.  Dietary Intake and Serum Selenium Levels Influence the Outcome of HTLV-1 Infection.

Authors:  Effat Saghi; Abdolreza Norouzy; Mohsen Nematy; Lida Jarahi; Reza Boostani; Fariba Zemorshidi; Zohreh Vahidi; Houshang Rafatpanah
Journal:  Biol Trace Elem Res       Date:  2020-11-09       Impact factor: 3.738

Review 2.  Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran.

Authors:  Mohammad Reza Hedayati-Moghaddam; Reza Jafarzadeh Esfehani; Hiba El Hajj; Ali Bazarbachi
Journal:  Viruses       Date:  2022-03-23       Impact factor: 5.818

3.  Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.

Authors:  Massanobu Takatani; Myuki Esashika Crispim; Nelson Fraiji; Mariane Martins Araujo Stefani; Dagmar Kiesslich
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

4.  The effect of HTLV1 infection on inflammatory and oxidative parameters in the liver, kidney, and pancreases of BALB/c mice.

Authors:  Saeed Niazmand; Arezoo Gowhari Shabgah; Sara Hosseinian; Jamshid Gholizadeh Navashenaq; Ali Kamali; Mohammad Reza Khazdair; Yousef Baghcheghi; Mahdiyeh Hedayati-Moghadam
Journal:  Physiol Rep       Date:  2022-04

5.  Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net).

Authors:  Ariella L G Coler-Reilly; Naoko Yagishita; Hiroko Suzuki; Tomoo Sato; Natsumi Araya; Eisuke Inoue; Ayako Takata; Yoshihisa Yamano
Journal:  Orphanet J Rare Dis       Date:  2016-05-25       Impact factor: 4.123

6.  Association between human T cell leukemia virus type-1 (HTLV-1) infection and advanced periodontitis in relation to atherosclerosis among elderly Japanese: a cross-sectional study.

Authors:  Yuji Shimizu; Hirotomo Yamanashi; Masayasu Kitamura; Reiko Furugen; Takahiro Iwasaki; Hideki Fukuda; Hideaki Hayashida; Koji Kawasaki; Kairi Kiyoura; Shin-Ya Kawashiri; Toshiyuki Saito; Atsushi Kawakami; Takahiro Maeda
Journal:  Environ Health Prev Med       Date:  2019-12-28       Impact factor: 3.674

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.